News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Reports Fourth Quarter and Year End 2017 Results

  • KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results

  • Positive Topline Results from KP415 PK Study in Children/Adolescents With ADHD

  • KemPharm to Present at Upcoming Investor Conferences

  • KemPharm Announces FDA Approval of Apadaz™

  • MoneyShow Orlando Conference

  • KP415 – APSARD 2018

  • KP201/IR – AAPM 2017

  • KP511 – AAPM 2017